Vera Therapeutics vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Vera Therapeutics Inc (VERA)

Q2 202617 Jun – 7 Jul 2026

▲3

Vera Wins FDA Accelerated Approval for TRUTAKNA, Eyes Full Approval

FDA Accelerated Approval of TRUTAKNA On July 7, the FDA granted accelerated approval to TRUTAKNA for IgA nephropathy, allowing Vera to sell the drug immediately. This is a major milestone that turns a pipeline story into a commercial one, boosting revenue prospects and investor confidence.
This is the single most important new event that directly answers why VERA is moving now.
FDA Agreement on Earlier Kidney Function Analysis Vera reached an agreement with the FDA to analyze kidney function data earlier than planned, potentially supporting full approval. This could speed up the path to broader approval and expand the patient population, increasing the drug's market potential.
This regulatory flexibility is a key new development that de-risks and accelerates the path to full approval.
Analyst Price Targets and PDUFA Anticipation Wells Fargo and LifeSci Capital reiterated Buy ratings with price targets of $70 and $90, citing atacicept's potential. Ahead of the July 7 PDUFA decision, the stock rose 6%, reflecting growing optimism about approval.
Analyst support and pre-decision momentum highlight market expectations that drive near-term price action.
Intensifying Competition in IgA Nephropathy Over 25 companies are developing 30+ drugs for IgA nephropathy, with several late-stage candidates. While Vera's approval gives it a first-mover advantage, competition could pressure long-term pricing and market share.
This provides a balanced view of the competitive landscape that could cap upside despite the approval.

June 202617 Jun – 7 Jul 2026

▲3

Vera Wins FDA Accelerated Approval for TRUTAKNA, Eyes Full Approval

FDA Accelerated Approval of TRUTAKNA On July 7, the FDA granted accelerated approval to TRUTAKNA for IgA nephropathy, allowing Vera to sell the drug immediately. This is a major milestone that turns a pipeline story into a commercial one, boosting revenue prospects and investor confidence.
This is the single most important new event that directly answers why VERA is moving now.
FDA Agreement on Earlier Kidney Function Analysis Vera reached an agreement with the FDA to analyze kidney function data earlier than planned, potentially supporting full approval. This could speed up the path to broader approval and expand the patient population, increasing the drug's market potential.
This regulatory flexibility is a key new development that de-risks and accelerates the path to full approval.
Analyst Price Targets and PDUFA Anticipation Wells Fargo and LifeSci Capital reiterated Buy ratings with price targets of $70 and $90, citing atacicept's potential. Ahead of the July 7 PDUFA decision, the stock rose 6%, reflecting growing optimism about approval.
Analyst support and pre-decision momentum highlight market expectations that drive near-term price action.
Intensifying Competition in IgA Nephropathy Over 25 companies are developing 30+ drugs for IgA nephropathy, with several late-stage candidates. While Vera's approval gives it a first-mover advantage, competition could pressure long-term pricing and market share.
This provides a balanced view of the competitive landscape that could cap upside despite the approval.

Latest17 Jun – 7 Jul 2026

▲3

Vera Wins FDA Accelerated Approval for TRUTAKNA, Eyes Full Approval

FDA Accelerated Approval of TRUTAKNA On July 7, the FDA granted accelerated approval to TRUTAKNA for IgA nephropathy, allowing Vera to sell the drug immediately. This is a major milestone that turns a pipeline story into a commercial one, boosting revenue prospects and investor confidence.
This is the single most important new event that directly answers why VERA is moving now.
FDA Agreement on Earlier Kidney Function Analysis Vera reached an agreement with the FDA to analyze kidney function data earlier than planned, potentially supporting full approval. This could speed up the path to broader approval and expand the patient population, increasing the drug's market potential.
This regulatory flexibility is a key new development that de-risks and accelerates the path to full approval.
Analyst Price Targets and PDUFA Anticipation Wells Fargo and LifeSci Capital reiterated Buy ratings with price targets of $70 and $90, citing atacicept's potential. Ahead of the July 7 PDUFA decision, the stock rose 6%, reflecting growing optimism about approval.
Analyst support and pre-decision momentum highlight market expectations that drive near-term price action.
Intensifying Competition in IgA Nephropathy Over 25 companies are developing 30+ drugs for IgA nephropathy, with several late-stage candidates. While Vera's approval gives it a first-mover advantage, competition could pressure long-term pricing and market share.
This provides a balanced view of the competitive landscape that could cap upside despite the approval.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.